f Commentary on the Role of Medicinal Cannabis in Healthy Aging and Neuroprotection

References

1. Nagpal R. Neth B.J. Wang S. Craft S. Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine 2019 47 529 542 10.1016/j.ebiom.2019.08.032 31477562
   [Google Scholar]
2. Gao L. Liu X. Luo X. Lou X. Li P. Li X. Liu X. Antiaging effects of dietary supplements and natural products. Front. Pharmacol. 2023 14 1192714 10.3389/fphar.2023.1192714 37441528
   [Google Scholar]
3. Wang Z. Arnold J.C. Cannabinoids and healthy ageing: The potential for extending healthspan and lifespan in preclinical models with an emphasis on Caenorhabditis elegans. Geroscience 2024 46 6 5643 5661 10.1007/s11357‑024‑01162‑8 38696056
   [Google Scholar]
4. Kaszyńska A.A. Cannabinoids: Potential for modulation and enhancement when combined with vitamin B12 in case of neurodegenerative disorders. Pharmaceuticals 2024 17 6 813 10.3390/ph17060813 38931480
   [Google Scholar]
5. Paes-Colli Y. Aguiar A.F.L. Isaac A.R. Ferreira B.K. Campos R.M.P. Trindade P.M.P. de Melo Reis R.A. Sampaio L.S. Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: From hypothesis to clinical practice. Front. Cell. Neurosci. 2022 16 917164 10.3389/fncel.2022.917164 35707521
   [Google Scholar]
6. Li H. Liu Y. Tian D. Tian L. Ju X. Qi L. Wang Y. Liang C. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. Eur. J. Med. Chem. 2020 192 112163 10.1016/j.ejmech.2020.112163 32109623
   [Google Scholar]
7. Bonini S.A. Premoli M. Tambaro S. Kumar A. Maccarinelli G. Memo M. Mastinu A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol. 2018 227 300 315 10.1016/j.jep.2018.09.004 30205181
   [Google Scholar]
8. Messina F Rosati O Curini M Marcotullio MC Cannabis and bioactive cannabinoids. Studies in Natural Products Chemistry Elsevier 2015 17 57 10.1016/B978‑0‑444‑63473‑3.00002‑2
   [Google Scholar]
9. Kratz J.W. García De Palau M. Handbook on medicinal cannabis. Kalapa Clinic 2018
   [Google Scholar]
10. Hanuš L.O. Meyer S.M. Muñoz E. Taglialatela-Scafati O. Appendino G. Phytocannabinoids: A unified critical inventory. Nat. Prod. Rep. 2016 33 12 1357 1392 10.1039/C6NP00074F 27722705
    [Google Scholar]
11. Marzorati S. Friscione D. Picchi E. Verotta L. Cannabidiol from inflorescences of Cannabis sativa L.: Green extraction and purification processes. Ind. Crops Prod. 2020 155 112816 10.1016/j.indcrop.2020.112816
    [Google Scholar]
12. Rochfort S. Isbel A. Ezernieks V. Elkins A. Vincent D. Deseo M.A. Spangenberg G.C. Utilisation of design of experiments approach to optimise supercritical fluid extraction of medicinal cannabis. Sci. Rep. 2020 10 1 9124 10.1038/s41598‑020‑66119‑1 32499550
    [Google Scholar]
13. Sun D. Li X. Nie S. Liu J. Wang S. Disorders of cancer metabolism: The therapeutic potential of cannabinoids. Biomed. Pharmacother. 2023 157 113993 10.1016/j.biopha.2022.113993 36379120
    [Google Scholar]
14. Aizpurua-Olaizola O. Elezgarai I. Rico-Barrio I. Zarandona I. Etxebarria N. Usobiaga A. Targeting the endocannabinoid system: Future therapeutic strategies. Drug Discov. Today 2017 22 1 105 110 10.1016/j.drudis.2016.08.005 27554802
    [Google Scholar]
15. Blebea N.M. Pricopie A.I. Vlad R.A. Hancu G. Phytocannabinoids: Exploring pharmacological profiles and their impact on therapeutical use. Int. J. Mol. Sci. 2024 25 8 4204 10.3390/ijms25084204 38673788
    [Google Scholar]
16. Rezende B. Alencar A.K.N. de Bem G.F. Fontes-Dantas F.L. Montes G.C. Endocannabinoid system: Chemical characteristics and biological activity. Pharmaceuticals 2023 16 2 148 10.3390/ph16020148 37017445
    [Google Scholar]
17. Fernández-Ruiz J. Berrendero F. Hernández M.L. Ramos J.A. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000 23 1 14 20 10.1016/S0166‑2236(99)01491‑5 10631784
    [Google Scholar]
18. Scotter E.L. Abood M.E. Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 2010 160 3 480 498 10.1111/j.1476‑5381.2010.00735.x 20590559
    [Google Scholar]
19. Cristino L. Bisogno T. Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 2020 16 1 9 29 10.1038/s41582‑019‑0284‑z 31831863
    [Google Scholar]
20. Fernández-Ruiz J. The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid‐based therapies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol. 2019 176 10 1370 1383 10.1111/bph.14382 29856067
    [Google Scholar]
21. Ghasemi-Gojani E. Kovalchuk I. Kovalchuk O. Cannabinoids and terpenes for diabetes mellitus and its complications: From mechanisms to new therapies. Trends Endocrinol. Metab. 2022 33 12 828 849 10.1016/j.tem.2022.08.003 36280497
    [Google Scholar]
22. Bilkei-Gorzo A. The endocannabinoid system in normal and pathological brain ageing. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012 367 1607 3326 3341 10.1098/rstb.2011.0388 23108550
    [Google Scholar]
23. Hodges E.L. Ashpole N.M. Aging circadian rhythms and cannabinoids. Neurobiol. Aging 2019 79 110 118 10.1016/j.neurobiolaging.2019.03.008 31035036
    [Google Scholar]
24. Piyanova A. Lomazzo E. Bindila L. Lerner R. Albayram O. Ruhl T. Lutz B. Zimmer A. Bilkei-Gorzo A. Age-related changes in the endocannabinoid system in the mouse hippocampus. Mech. Ageing Dev. 2015 150 55 64 10.1016/j.mad.2015.08.005 26278494
    [Google Scholar]
25. Bilkei-Gorzo A. Racz I. Valverde O. Otto M. Michel K. Sarstre M. Zimmer A. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc. Natl. Acad. Sci. USA 2005 102 43 15670 15675 10.1073/pnas.0504640102 16221768
    [Google Scholar]
26. García S. Martín Giménez V.M. Mocayar Marón F.J. Reiter R.J. Manucha W. Melatonin and cannabinoids: Mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases. Histol. Histopathol. 2020 35 8 789 800 10.14670/HH‑18‑212 32154907
    [Google Scholar]
27. Bilkei-Gorzo A. Albayram O. Draffehn A. Michel K. Piyanova A. Oppenheimer H. Dvir-Ginzberg M. Rácz I. Ulas T. Imbeault S. Bab I. Schultze J.L. Zimmer A. A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice. Nat. Med. 2017 23 6 782 787 10.1038/nm.4311 28481360
    [Google Scholar]
28. Sarne Y. Toledano R. Rachmany L. Sasson E. Doron R. Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol. Neurobiol. Aging 2018 61 177 186 10.1016/j.neurobiolaging.2017.09.025 29107185
    [Google Scholar]
29. Yoo H.B. DiMuzio J. Filbey F.M. Interaction of cannabis use and aging: From molecule to mind. J. Dual Diagn. 2020 16 1 140 176 10.1080/15504263.2019.1665218 31570066
    [Google Scholar]
30. Shapira G. Israel-Elgali I. Grad M. Avnat E. Rachmany L. Sarne Y. Shomron N. Hippocampal differential expression underlying the neuroprotective effect of delta-9-tetrahydrocannabinol microdose on old mice. Front. Neurosci. 2023 17 1182932 10.3389/fnins.2023.1182932 37534036
    [Google Scholar]
31. Kochman L.J. dos Santos A.A. Fornal C.A. Jacobs B.L. Despite strong behavioral disruption, Δ9-tetrahydrocannabinol does not affect cell proliferation in the adult mouse dentate gyrus. Brain Res. 2006 1113 1 86 93 10.1016/j.brainres.2006.07.080 16930565
    [Google Scholar]
32. Fan N. Yang H. Zhang J. Chen C. Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Δ9‐THC exposure‐impaired hippocampal synaptic plasticity. J. Neurochem. 2010 112 3 691 702 10.1111/j.1471‑4159.2009.06489.x 19912468
    [Google Scholar]
33. Nidadavolu P. Bilkei-Gorzo A. Krämer M. Schürmann B. Palmisano M. Beins E.C. Madea B. Zimmer A. Efficacy of Δ9-tetrahydrocannabinol (THC) alone or in combination with a 1:1 ratio of cannabidiol (CBD) in reversing the spatial learning deficits in old mice. Front. Aging Neurosci. 2021 13 718850 10.3389/fnagi.2021.718850 34526890
    [Google Scholar]
34. Weinstein G. Sznitman S.R. The implications of late-life cannabis use on brain health: A mapping review and implications for future research. Ageing Res. Rev. 2020 59 101041 101041 10.1016/j.arr.2020.101041 32109605
    [Google Scholar]
35. Gruber S.A. Sagar K.A. Dahlgren M.K. Gonenc A. Smith R.T. Lambros A.M. Cabrera K.B. Lukas S.E. The grass might be greener: Medical Marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. Front. Pharmacol. 2018 8 983 10.3389/fphar.2017.00983 29387010
    [Google Scholar]
36. McKetin R. Parasu P. Cherbuin N. Eramudugolla R. Anstey K.J. A longitudinal examination of the relationship between cannabis use and cognitive function in mid-life adults. Drug Alcohol Depend. 2016 169 134 140 10.1016/j.drugalcdep.2016.10.022 27810656
    [Google Scholar]
37. Auer R. Vittinghoff E. Yaffe K. Künzi A. Kertesz S.G. Levine D.A. Albanese E. Whitmer R.A. Jacobs D.R. Jr Sidney S. Glymour M.M. Pletcher M.J. Association between lifetime marijuana use and cognitive function in middle age. JAMA Intern. Med. 2016 176 3 352 361 10.1001/jamainternmed.2015.7841 26831916
    [Google Scholar]